Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02530203
Other study ID # SCS-PAF
Secondary ID
Status Terminated
Phase N/A
First received May 11, 2015
Last updated April 5, 2016
Start date February 2015
Est. completion date February 2016

Study information

Verified date April 2016
Source Medtronic BRC
Contact n/a
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

Patients will be randomized to control and spinal cord stimulation arm (SCS) to investigate the effect of SCS on the occurrence of post-operative atrial fibrillation in the five days after surgery.


Description:

Pre market single center clinical research feasibility study. Non blinded randomized controlled study. 52 patients undergoing CABG procedure will be enrolled and randomized into two different group (26 person each): the Spinal Cord Stimulation (SCS) and the control group. The first group will be implanted before the CABG procedure with a temporary SCS lead (5 days) while the second one will not. The lead will be connected to an external stimulator.

The day of the CABG surgery, before the scheduled procedure, the patients in the treatment group will be implanted with the SCS lead. CABG procedure follows the SCS lead implantation. SCS will be switched off before surgery.

After the CABG procedure, all patients will be hospitalized for minimally five days at the end of which they will be discharged. The Primary Endpoint data will be collected from the day of CABG procedure (Day-0) until Day-5. SCS lead will be removed on Day-5.

1-week follow up visit will be performed one week after discharge. End-points will be evaluated at various time before, during and after surgery. In both groups arrhythmic episodes for primary and secondary endpoints will be recorded via a Holter monitor (recording 5 days continuously).


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date February 2016
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients which will be subjected to an OFF-pump CABG procedure

2. More than 18 years of age

3. Subject is able and willing to give informed consent.

Exclusion Criteria:

1. Patients with known history of atrial arrhythmias.

2. Patients who are not treated with ß-blockers unless heart rate is too low for ß-blockers assumption.

3. Participation in another clinical trial which may affect the outcome within 3 months prior to day of procedure.

4. Other surgical interventions (e.g. valve replacement) programmed in the same surgical session

5. Resting pulse rate =45 beats / min as assessed before daily doses of ß-blockage is administered.

6. Hypotension (RR systolic <100 or RR diastolic <50).

7. Conduction abnormalities on the ECG consisting of a 1st degree atrioventricular block or a complete bundle branch block.

8. Subject is diagnosed with epilepsy or history of seizures.

9. Coagulation abnormalities as determined by anticoagulation guidelines for neuroaxial procedures 2011.

10. Patients not stabilized on an anti-arrhythmic drug regimen for the last 30 days.

11. Patients with long QT syndrome.

12. Patients with Brugada syndrome.

13. Patients affected by Polyneuropathy (e.g. due to diabetes).

14. Patients affected by pericarditis

15. Patients who underwent procedures in the past, which are expected to have changed the innervation of the heart for example:

- Ablation procedure

- Cardiac surgery

16. Pregnant patients or nursing (subjects who are of child bearing potential and are not on a reliable form of birth control will undergo a pregnancy test)

17. Patients already implanted with cardiac devices

18. Patients with existing implanted neurostimulators

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Spinal Cord Stimulation System
High frequency stimulation using a catheter placed in the lumen of the spine to inhibit sympathetic outflow to the heart
Holter Recording_ NEMon DR220 Holter Recorders
To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.

Locations

Country Name City State
Netherlands Medisch Spectrum Twente (MST) Enschede

Sponsors (1)

Lead Sponsor Collaborator
Medtronic BRC

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Atrial fibrillation AT/AF will be defined as an episode with an atrial rate >175 bpm lasting = 20 seconds. 5 days after CABG No
Secondary Medication Description of integral medication related to AT/AF occurrence and pain in the treatment (SCS) and control group between start of anesthesia and 5 days after surgery. 5 days after CABG No
Secondary Cardioversion Description of number of cardioversion needed in the treatment (SCS) and control group between start of anesthesia and 5 days after surgery. 5 days after CABG No
Secondary Hospitalizations Days Description of hospitalizations longer than 5 days as required by the protocol and clinical practice in the treatment (SCS) and control group. 1 week after discharge No
Secondary BP Description of 1) intra arterial blood pressure as averaged over the first 24 hours after surgery and 2) arterial blood pressure as determined using a blood pressure cuff at a specific time on Day-2, Day-3, Day-4 and Day-5 after surgery in the treatment (SCS) and control group. 5 days after CABG No
Secondary Description of the total number of AT/AF episodes in the treatment (SCS) and control group between start of anesthesia and 5 days after surgery. AT/AF episodes 5 days after CABG No
Secondary Description of burden of AT/AF episodes in the treatment (SCS) and control group between start of anesthesia and 5 days after surgery. AT/AF burden 5 days after CABG No
Secondary Premature atrial beats Description of the amount of premature atrial beats in the treatment (SCS) and control group from the end of the procedure till Day-5 after surgery. 5 days after CABG No
Secondary VT/VF episodes Description of the total number of VT/VF episodes in the treatment (SCS) and control group between start of anesthesia and 5 days after surgery. 5 days after CABG No
Secondary Burden VT/VF episodes Description of the burden of VT/VF episodes in the treatment (SCS) and control group between start of anesthesia and 5 days after surgery. 5 days after CABG No
Secondary HRV Improvement LF/HF ratio of Heart Rate Variability (HRV) by SCS. SCS On and Off will be compared in each patients in the treatment (SCS) group before surgery and 5 days after surgery. 5 days after CABG No
Secondary Pain on the VAS scale Description of pain-score due to CABG surgery measured with a VAS score three times a from Day-1 till Day-5 after surgery in the treatment (SCS) and control group. 5 days after CABG No
Secondary Bladder function The extra time the bladder catheter will be kept in the patients after the first 2 days after surgery will be described in the treatment (SCS) and control group in order to assess bladder function. 5 days after CABG No
Secondary HR Description of 1) heart rate as averaged over the first 24 hours after surgery and 2) heart rate as determined using a blood pressure cuff at a specific time on Day-2, Day-3, Day-4 and Day-5 after surgery in the treatment (SCS) and control group. 5 days after CABG No
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A